CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

apixaban

Trade name: eliquis

Small moleculeapprovedFast Track FDA

Approved

Dec 28, 2012

Apixaban is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. Apixaban has been available in Europe since May 2012. An FDA decision on apixaban which was expected on June 28, 2012 was initially delayed before final approval on December 28, 2012. On August 21, 2014, Pfizer announced that apixaban was now FDA approved for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures. — NCATS

Clinical trial activity

229 trials · 231 clinical orgs · 21 marketing orgs

Phase 1
43
Phase 2
103
Phase 3
66
Phase 4
61

Earliest trial started Oct 1, 2004 (NCT00097357)

Timeline

2000s

  1. Jan 1, 2004

    Bristol-Myers Squibb — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Bristol-Myers Squibb — Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2006

    Bristol-Myers Squibb — Earliest Phase 3 Sponsor(trial)

2010s

  1. Dec 28, 2012

    Bristol-Myers Squibb — Earliest FDA Approval

  2. Dec 28, 2012

    Bristol-Myers Squibb — NDA Organization

  3. Dec 17, 2018

    Esteve Labs — Marketing Organization

  4. Jan 4, 2019

    Torrent Pharmaceuticals Limited — Marketing Organization

  5. Feb 1, 2019

    Micro Labs Ltd India — Marketing Organization

  6. Feb 8, 2019

    Sunshine Lake Pharma Co., Ltd. — Marketing Organization

  7. Feb 22, 2019

    Sun Pharmaceuticals — Marketing Organization

  8. Jul 3, 2019

    Mylan — Marketing Organization

2020s

  1. Mar 2, 2020

    Dr. Reddy's Laboratories — Marketing Organization

  2. Apr 8, 2020

    Bionpharma Inc — Marketing Organization

  3. Jul 2, 2020

    Teva — Marketing Organization

  4. Jul 28, 2020

    Accord Research — Marketing Organization

  5. Aug 19, 2020

    Impax Laboratories — Marketing Organization

  6. Aug 19, 2020

    Amneal Pharmaceuticals — Marketing Organization

  7. Sep 11, 2020

    Indoco Remedies — Marketing Organization

  8. Feb 1, 2022

    Sigmapharm Laboratories — Marketing Organization

  9. Apr 12, 2022

    Prinston Inc — Marketing Organization

  10. Jun 21, 2022

    ZHEJIANG YONGNING PHARMACEUTICAL CO LTD — Marketing Organization

  11. Feb 27, 2023

    Hetero Labs Ltd — Marketing Organization

  12. Feb 27, 2023

    Zydus Discovery DMCC — Marketing Organization

  13. May 26, 2023

    Aurobindo Pharma — Marketing Organization

  14. Feb 16, 2024

    Apotex — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewFast trackDec 28, 2012

Chemistry & pharmacology

Loading structure…

SMILES

COC1=CC=C(C=C1)N2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O
Mol. weight
459.4971 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixaban
  • apixabán
  • apixabán
  • apixabanum
  • apixabanum
  • apixiban
  • bms562247
  • bms 562247
  • bms 562247
  • bms-562247
  • bms-562247
  • bms-562247
  • bms-562247
  • bms-562247-01
  • bms-562247-01
  • bms-562247-01
  • eliquis
  • eliquis
  • eliquis
  • eliquis
  • eliquis

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07160686Phase 3Mar 2, 2026University of Birmingham
NCT07312851Phase 1Jan 12, 2026AstraZeneca, Parexel
NCT07237308Phase 4Dec 31, 2025Yonsei University
NCT07246005Phase 2Dec 1, 2025University of London
NCT07265466Phase 1Nov 17, 2025Onconic Therapeutics Inc.
NCT07189897Phase 4Oct 31, 2025State University of New York, Syracuse
NCT07175428Phase 2Oct 20, 2025Regeneron
NCT06933056Early Phase 1 (Phase 1)Sep 2, 2025Lexicon Pharmaceuticals, University of Michigan
NCT07005024Phase 3Aug 31, 2025University of Vermont
NCT07015905Phase 3Jun 25, 2025Regeneron
NCT06953726Phase 4Jun 2, 2025Department of Veteran Affairs, Food and Drug Administration
NCT06866665N/AMar 31, 2025Yonsei University
NCT06864052N/AMar 1, 2025Ewha Womans University
NCT06886516Early Phase 1 (Phase 1)Feb 28, 2025Harvard University
NCT06729034Phase 2Feb 1, 2025University of Oslo
NCT06650501Phase 4Jan 7, 2025McGill University, University of Melbourne
NCT06742567Phase 3Dec 2, 2024Government of Pakistan
NCT06862726Phase 4Dec 1, 2024Les Laboratoires des Médicaments Stériles
NCT06689436Phase 2Nov 30, 2024Novum Pharmaceutical Research Services, TAHO Pharmaceuticals Ltd.
NCT07270263N/ANov 22, 2024Medical University of Gdansk
Showing 20 of 229 trials
Page 1 / 12

Organizations

Research & Development (231)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit663152004
PfizerFor profit31742006
McMaster UniversityAcademic/Hospital11742006
Duke UniversityAcademic/Hospital9422009
University of OttawaAcademic/Hospital7732013
Yonsei UniversityAcademic/Hospital7722015
Canadian Institutes of Health Research (CIHR)Academic/Hospital6022014
Harvard UniversityAcademic/Hospital5532015
Assistance Publique - Hôpitaux de ParisAcademic/Hospital4422018
BayerFor profit4322013
Mayo ClinicAcademic/Hospital4432015
National Heart, Lung, and Blood Institute (NHLBI)Government4022012
University of BernAcademic/Hospital4432017
University of LondonAcademic/Hospital4232019
Aarhus UniversityAcademic/Hospital3222018
Hamilton Health Sciences CorporationAcademic/Hospital3122016
Karolinska InstituteAcademic/Hospital3132018
McGill UniversityAcademic/Hospital3222013
RegeneronFor profit3322023
Thomas Jefferson UniversityAcademic/Hospital3312014
231 organizations
Page 1 / 12

Marketing (25)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGJul 28, 2020
Amneal PharmaceuticalsFor profitMKTGAug 19, 2020
ApotexFor profitMKTGFeb 16, 2024
Aurobindo PharmaFor profitMKTGMay 26, 2023
Bionpharma IncFor profitMKTGApr 8, 2020
Bionpharma IncFor profitSYNApr 8, 2020
Bristol-Myers SquibbFor profitNDADec 28, 2012
Dr. Reddy's LaboratoriesFor profitMKTGMar 2, 2020
Esteve LabsFor profitMKTGDec 17, 2018
Esteve LabsFor profitSYNJul 26, 2021
Hetero Labs LtdFor profitMKTGFeb 27, 2023
Impax LaboratoriesFor profitMKTGAug 19, 2020
Indoco RemediesFor profitMKTGSep 11, 2020
Micro Labs Ltd IndiaFor profitSYNFeb 1, 2019
Micro Labs Ltd IndiaFor profitMKTGFeb 1, 2019
MylanFor profitMKTGJul 3, 2019
Prinston IncFor profitMKTGApr 12, 2022
Sigmapharm LaboratoriesFor profitMKTGFeb 1, 2022
Sun PharmaceuticalsFor profitMKTGFeb 22, 2019
Sunshine Lake Pharma Co., Ltd.For profitMKTGFeb 8, 2019
TevaFor profitMKTGJul 2, 2020
Torrent Pharmaceuticals LimitedFor profitMKTGJan 4, 2019
Torrent Pharmaceuticals LimitedFor profitSYNDec 17, 2024
ZHEJIANG YONGNING PHARMACEUTICAL CO LTDFor profitMKTGJun 21, 2022
Zydus Discovery DMCCFor profitMKTGFeb 27, 2023